Business Wire

New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI® approved in Europe

Share

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced that the European Commission (EC) has approved both NILEMDO® (bempedoic acid) and NUSTENDI ® (bempedoic acid / ezetimibe) for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia in Europe.4,5 Bempedoic acid has a unique mechanism of action which is complementary to statins and other lipid-lowering therapies (LLTs) allowing additional LDL-C lowering on top of other LLTs compared to placebo.6 Both approvals were supported by data from the CLEAR trial programme conducted in more than 4,000 high- and very high-risk patients.6-10

Across Europe, cardiovascular disease is one of the major causes of death killing more than four million people every year. High LDL-C is one of the major causes for heart attacks, strokes and other events that can lead to death,” said Professor Alberico L. Catapano, Chairperson of the guidelines Task Force and Professor of Pharmacology at the Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy. “ESC/EAS Guidelines recommend intensively lowering LDL-C to reduce cardiovascular risk. The approval of bempedoic acid and its fixed dose combination with ezetimibe gives us important new treatment options that can be combined with other lipid-lowering treatments to help reduce LDL-C in people at risk of events like heart attacks and strokes.”

NILEMDO® is a new, first-in-class, affordable, oral treatment which lowers cholesterol, and can be combined with other oral treatments to help lower cholesterol even further. It provides additional LDL-C lowering of up to 28% on top of other lipid-lowering therapies, compared to placebo by inhibiting ATP Citrate Lyase (ACL), an enzyme in the well-known cholesterol synthesis pathway, upstream of the statin target in the liver.4,9

NUSTENDI® is a fixed dose combination tablet of bempedoic acid and ezetimibe which combines two complementary ways of reducing cholesterol in a convenient, once-daily, oral treatment with the potential to support adherence to treatment by reducing pill burden for patients. Bempedoic acid inhibits cholesterol production in the liver while ezetimibe reduces absorption of dietary cholesterol in the gut.8,11 In a Phase 3 clinical trial NUSTENDI® reduced LDL-C by 38% compared to placebo in high-risk patients already taking maximum-tolerated statin therapy.8

A combined safety analysis in more than 3,600 patients confirms that bempedoic acid is well tolerated, and overall adverse event rates were similar to placebo.12 Due to its novel mechanism of action, NILEMDO® is not activated in skeletal muscle which decreases the potential for muscle-related adverse effects.4,13

Up to 80% of patients do not reach guideline-recommended LDL-C goals despite receiving treatments such as statins, and are at increased risk of a heart attack or stroke.1,2,3

Due to the limitations of existing lipid-lowering therapies, the need for additional add-on treatments remains to help people reach their LDL-C goals and to reduce cardiovascular risk,” said Benoit Creveau, Head of Cardiovascular Marketing at Daiichi Sankyo Europe. “NILEMDO® and NUSTENDI® can be added to existing, oral lipid-lowering therapies and will help HCPs and their patients at high- and very high-risk to take back control. The approval of NILEMDO® and NUSTENDI® in Europe is a key milestone for us at Daiichi Sankyo Europe and reflects our ongoing commitment to reducing the burden of cardiovascular disease.”

- ENDS –

About NILEMDO®
With a unique mechanism of action, NILEMDO® is a new, first-in-class, affordable, oral treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.4 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.4

NILEMDO® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:4

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

NILEMDO® acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, with a unique mechanism of action which allows additional LDL-C lowering when added to statin treatment.4 Due to its novel mechanism of action, NILEMDO® is not activated in skeletal muscle.4

About NUSTENDI®
NUSTENDI® is a new oral treatment which combines two complementary ways of reducing cholesterol in a convenient once-daily tablet. NUSTENDI® is a fixed dose combination tablet containing bempedoic acid (the active pharmaceutical ingredient in NILEMDO®) and ezetimibe.5

NUSTENDI® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:5

  • in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,
  • alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,
  • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin.

Daiichi Sankyo Europe has licensed exclusive commercialisation rights to these products in the European Economic Area and Switzerland from Esperion. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.


1 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020 Jan 1;41(1):111-188 doi:10.1093/eurheartj/ehz455.

2 Fox KM, et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol 2018; 107: 380–388.

3 Kotseva K, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardio. 2019;26(8):824–835.

4 European Medicines Agency. Nilemdo® Summary of Product Characteristics. March 2020.

5 European Medicines Agency. Nustendi® Summary of Product Characteristics. March 2020.

6 Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.

7 Goldberg AC, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780–1788. doi:10.1001/jama.2019.16585.

8 Ballantyne, CM, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2019; doi 10.1177/2047487319864671.

9 Ballantyne CM, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.

10 Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019; 380:1022–32.

11 Phan BAP et al. Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management 2012:8 415–427.

12 Ballantyne, CM, et al. Safety profile of bempedoic acid: pooled analysis of 4 phase 3 clinical trials. Abstract: P5364.

13 Pinkosky SL, et al. Liver- specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications. 2016; 7:13457. DOI:10.1038/ncomms13457.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lydia Worms (Europe)
Daiichi Sankyo Europe GmbH
Communications & Product PR Europe
+49 (89) 7808751

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

G42 Launches OpenAI GPT-OSS Globally on Core42's AI Cloud13.8.2025 19:26:00 EEST | Press release

Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced the availability of OpenAI’s latest open-weight AI models, including gpt-oss-20B and gpt-oss-120B, on the Core42 AI Cloud platform, instantly accessible through the Core42 Compass API. The deployment enables enterprises, researchers, and developers to run the models on a choice of leading silicon platforms with sovereign, scalable, and high-performance capabilities. Integrated into Compass API with the flexibility to access a wide spectrum of high-performance compute platforms, Core42 delivers industry-leading inference speeds of up to 3,000 tokens per second per user, enabling real-time AI at global scale while aligning workloads with the optimal infrastructure for price-performance and scalability. This deployment delivers tailored performance for low-latency inference workloads and applications, reinforcing Core42’s commitment to secure and optimized global sovereign-enabled AI infrastructure. “Co

Cross-Platform Developers Get Full Control Over Game Distribution With New Features for Xsolla Publishing Suite13.8.2025 19:00:00 EEST | Press release

Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today a major expansion of its Publishing Suite, a one-stop modular solution built for PC, web, and cross-platform games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813620658/en/ (Graphic: Xsolla) As development and marketing costs continue to rise, developers and publishers are seeking new high-margin revenue streams that complement their existing strategies on Steam, Epic, and console. The Publishing Suite is uniquely positioned to help teams enable direct-to-consumer monetization regardless of a game's genre, size, and lifecycle stage. With full control over distribution, storefronts, and player engagement, studios can tailor the experience to any business model or use case. The latest updates to the Xsolla Publishing Suite further enhance its value for free-to-play (F2P) and buy-to-play (B2P) games, enabling faste

LambdaTest Unveils the Fourth Edition of the Testµ ('TestMu') Conference in 202513.8.2025 19:00:00 EEST | Press release

LambdaTest, a leading GenAI-native quality engineering platform, is excited to unveil the 4th edition of its flagship Testµ (‘TestMu’) Conference, taking place virtually from August 19–21, 2025. This year’s event is set to host over 50,000 quality, engineering, and DevOps professionals from more than 120 countries, making it one of the largest online global gatherings dedicated to the future of quality engineering. Testµ (‘TestMu’) Conference 2025 is designed to explore cutting-edge trends, emerging tools, and breakthrough innovations shaping the world of technology. With an esteemed lineup of 100+ global speakers, the conference will feature some of the most influential voices in tech, including Angie Jones, Global Vice President of Developer Relations of Block; Bratin Saha, Chief Product and Technology Officer of DigitalOcean; Dana Lawson, Chief Technology Officer of Netlify; Luis Héctor Chávez, Chief Technology Officer of Replit; Subba Ramaswamy, Managing Director of Accenture; and

Incentive and Recognition Insight on a Global Scale13.8.2025 18:20:00 EEST | Press release

The Incentive Marketing Association (IMA) undertook an extensive year-long global research project to deliver data that is designed to provide actionable incentive and recognition strategy for customer engagement and brand loyalty. The Incentive & Recognition Insights 2025 report synthesizes insights from over 600 executives worldwide, offering comprehensive global benchmarks and trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806639332/en/ IMA Global Market Report Cover “We hoped this study would provide a unified voice to represent the global industry," says Fintan Connolly, Consultant at Engage Loyalty, Research Chair, and past President of IMA Global. “We ran a comprehensive survey to get hard numbers and benchmarks, and we collected open-ended feedback and regional insights so we could capture the stories and context behind the numbers." As part of the global report, nine exclusive reports were developed, prov

Celebrating the Osaka-Kansai Expo 2025 “Top Chef in OSAKA 2025” Featuring Massimo Bottura13.8.2025 18:00:00 EEST | Press release

To commemorate the Osaka-Kansai Expo 2025, the Come to Osaka Campaign Executive Committee—led by Osaka Prefecture, Osaka City, and the Osaka Convention & Tourism Bureau—will present a special culinary event: Top Chef in OSAKA 2025, featuring world-renowned Chef Massimo Bottura. From September 9 to 14, 2025, Chef Bottura will offer exclusive lunch and dinner courses at Restaurant SAKURA, Hotel New Otani Osaka. Located on the 18th floor, the elegant French restaurant offers panoramic views of Osaka Castle and lush surroundings. Chef Bottura’s bespoke menu will showcase the rich agricultural and culinary heritage of Osaka, with most ingredients sourced locally. This initiative supports regional farmers, producers, and chefs, while promoting Osaka’s culinary excellence on a global stage. Massimo Bottura is the chef patron of Osteria Francescana, a three-Michelin-starred and Michelin Green Starred restaurant in Modena, Italy, and a two-time winner of The World’s 50 Best Restaurants. He is a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye